Biolinerx Stock Short Ratio
| BLRX Stock | USD 0.27 0.01 3.57% |
BioLineRx fundamentals help investors to digest information that contributes to BioLineRx's financial success or failures. It also enables traders to predict the movement of BioLineRx Stock. The fundamental analysis module provides a way to measure BioLineRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLineRx stock.
BioLineRx | Short Ratio |
BioLineRx Company Short Ratio Analysis
BioLineRx's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current BioLineRx Short Ratio | 2.39 X |
Most of BioLineRx's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLineRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioLineRx Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for BioLineRx is extremely important. It helps to project a fair market value of BioLineRx Stock properly, considering its historical fundamentals such as Short Ratio. Since BioLineRx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioLineRx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioLineRx's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
BioLineRx Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, BioLineRx has a Short Ratio of 2.39 times. This is 38.72% lower than that of the Biotechnology sector and 67.75% lower than that of the Health Care industry. The short ratio for all United States stocks is 40.25% higher than that of the company.
BioLineRx Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLineRx's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLineRx could also be used in its relative valuation, which is a method of valuing BioLineRx by comparing valuation metrics of similar companies.BioLineRx is currently under evaluation in short ratio category among its peers.
BioLineRx Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioLineRx from analyzing BioLineRx's financial statements. These drivers represent accounts that assess BioLineRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioLineRx's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 22.8M | 43.3M | 92.2M | 34.5M | 104.2M | 68.4M | |
| Enterprise Value | 27.9M | 34.2M | 83.8M | 36.3M | 111.5M | 117.1M |
BioLineRx Institutional Holders
Institutional Holdings refers to the ownership stake in BioLineRx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioLineRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioLineRx's value.| Shares | Two Sigma Securities, Llc | 2024-06-30 | 46.2 K | Xtx Topco Ltd | 2024-09-30 | 44.1 K | Orin Green Financial, Llc | 2024-09-30 | 43 K | Geode Capital Management, Llc | 2024-09-30 | 40 K | Rathbone Brothers Plc | 2024-06-30 | 39.8 K | Gradient Investments | 2024-09-30 | 30 K | Rhumbline Advisers | 2024-06-30 | 25.7 K | Weaver Consulting Group | 2024-06-30 | 16.9 K | Cutter & Co Brokerage, Inc. | 2024-09-30 | 16.7 K | Alyeska Investment Group, L.p. | 2024-09-30 | 866.5 K | Cvi Holdings Llc | 2024-06-30 | 815.7 K |
BioLineRx Fundamentals
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.77) % | ||||
| Operating Margin | (1.07) % | ||||
| Current Valuation | 25.74 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Shares Owned By Insiders | 8.53 % | ||||
| Shares Owned By Institutions | 3.09 % | ||||
| Number Of Shares Shorted | 1.06 M | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 1.59 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 4.8 M | ||||
| EBITDA | (57.06 M) | ||||
| Net Income | (60.61 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 11.59 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (22.61 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Price To Earnings To Growth | 0.20 X | ||||
| Target Price | 9.83 | ||||
| Number Of Employees | 79 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 22.23 M | ||||
| Total Asset | 63.92 M | ||||
| Retained Earnings | (390.61 M) | ||||
| Working Capital | 16.33 M | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
| Net Asset | 63.92 M |
About BioLineRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLineRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLineRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLineRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.